News
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...
Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...
Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...
Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower second-quarter results due to persistently weak demand for its Gardasil vaccine in ...
The Gardasil human papillomavirus virus vaccine remains Merck’s second best-selling drug behind cancer treatment Keytruda.
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...
CEO Rob Davis referred to the cost reduction program as a 'reallocation' rather than a cut, with the savings to be reinvested ...
Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...
In the second quarter, Gardasil sales fell 55%, driven by the pause in China. Excluding China, Gardasil sales declined 3%.
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.
Merck CFO Caroline Litchfield tried to reassure investors and said that "Gardasil China represents a fraction of our company now, much less than 1%, we're not counting on it for growth." ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results